Bruker 公司
BRKR
54.80
-1.74
-3.08%
Bruker 公司
US · BRKR
#1504 按市值排名
上市于 1970
54.80
-1.74
-3.08%
实时 - 追踪5344个代码 - 心跳于242秒前
· 2026-10-16 20:02
✦ 量化财务健康度 计算方式说明
一般
- 奥特曼 Z 值为2.73，处于1.8至3.0的"灰色区"。
- 该模型对工业和制造业公司最为可靠，对银行、保险等金融类公司参考意义较弱。
营收 年度数据，近8年
最近年度同比+2.08%
利润率
- 毛利率
- 45.91%
- 营业利润率
- 6.87%
- 净利率
- -0.65%
关键比率与质量指标
奥特曼 Z 值低于约1.8提示财务困境风险，高于约3.0提示风险较低；该模型对工业和制造业公司最为可靠，对银行等金融类公司参考意义较弱。
利润表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 营收 | 1.90B | 2.07B | 1.99B | 2.42B | 2.53B | 2.96B | 3.37B | 3.44B |
| 毛利润 | 900.00M | 995.30M | 939.80M | 1.21B | 1.31B | 1.51B | 1.65B | 1.58B |
| 销售及管理费用 | 449.20M | 502.30M | 474.50M | 562.30M | 607.40M | 729.40M | 893.80M | 946.50M |
| 研发费用 | 173.40M | 187.70M | 198.00M | 220.80M | 235.90M | 294.80M | 376.50M | 395.20M |
| 营业利润 | 277.40M | 305.30M | 267.30M | 426.50M | 462.40M | 489.10M | 379.20M | 236.00M |
| 税前利润 | 244.70M | 280.40M | 225.80M | 393.60M | 413.90M | 544.20M | 206.90M | 22.00M |
| 税费 | 63.70M | 82.40M | 64.40M | 113.00M | 116.40M | 117.70M | 91.40M | 29.30M |
| 净利润 | 181.00M | 198.00M | 161.40M | 280.60M | 298.50M | 428.50M | 113.80M | -8.30M |
| 基本每股收益 | 1 | 1 | 1 | 2 | 2 | 3 | 1 | 0 |
| 稀释每股收益 | 1.14 | 1.26 | 1.02 | 1.81 | 1.99 | 2.90 | 0.76 | -0.15 |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 营收 | 801.40M | 797.40M | 860.50M | 977.20M | 823.40M | 838.50M |
| 毛利润 | 391.20M | 357.90M | 379.40M | 449.20M | 379.80M | 416.00M |
| 销售及管理费用 | 225.40M | 231.40M | 242.50M | 247.20M | 242.10M | 238.90M |
| 研发费用 | 97.10M | 100.20M | 98.30M | 99.60M | 101.30M | 94.30M |
| 营业利润 | 68.70M | 26.30M | 35.00M | 111.80M | 36.40M | 82.80M |
| 税前利润 | 25.10M | 500.00K | -71.80M | 68.20M | 21.90M | -40.70M |
| 税费 | 8.70M | -3.10M | -14.10M | 37.80M | 2.50M | 14.20M |
| 净利润 | 16.80M | 4.20M | -58.50M | 29.20M | 15.70M | -50.90M |
| 基本每股收益 | 0 | 0 | 0 | 0 | 0 | 0 |
| 稀释每股收益 | 0.11 | 0.05 | -0.41 | 0.10 | 0.02 | -0.41 |
资产负债表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 流动资产总额 | 1.30B | 1.80B | 1.93B | 2.47B | 2.11B | 2.16B | 2.05B | 2.21B |
| 现金及短期投资 | 322.40M | 684.90M | 731.80M | 1.17B | 645.50M | 488.30M | 183.40M | 298.80M |
| 存货 | 509.60M | 577.20M | 692.30M | 710.10M | 800.10M | 968.30M | 1.07B | 1.09B |
| 总资产 | 2.13B | 2.77B | 3.05B | 3.65B | 3.61B | 4.25B | 5.81B | 6.24B |
| 流动负债总额 | 599.30M | 645.60M | 791.90M | 938.50M | 914.30M | 1.20B | 1.28B | 1.28B |
| 短期负债 | 18.50M | 21.10M | 23.50M | 130.30M | 35.10M | 144.50M | 64.60M | 51.80M |
| 长期负债 | 322.60M | 812.80M | 842.30M | 1.22B | 1.20B | 1.16B | 2.06B | 1.85B |
| 总负债 | 1,200,900,000.00 | 1,833,300,000.00 | 2,074,700,000.00 | 2,565,200,000.00 | 2,480,000,000.00 | 2,836,600,000.00 | 3,991,500,000.00 | 3,731,100,000.00 |
| 股东权益总额 | 927.70M | 938.20M | 974.30M | 1.08B | 1.13B | 1.41B | 1.82B | 2.51B |
| 留存收益 | 1.10B | 1.27B | 1.41B | 1.66B | 1.93B | 2.32B | 2.41B | 2.36B |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 流动资产总额 | 2.11B | 2.16B | 2.35B | 2.21B | 2.10B | 2.23B |
| 现金及短期投资 | 184.20M | 92.00M | 293.10M | 298.80M | 133.40M | 222.50M |
| 存货 | 1.12B | 1.22B | 1.20B | 1.09B | 1.12B | 1.12B |
| 总资产 | 5.93B | 6.34B | 6.43B | 6.24B | 6.13B | 6.05B |
| 流动负债总额 | 1.34B | 1.35B | 1.27B | 1.28B | 1.36B | 1.20B |
| 短期负债 | 37.70M | 55.70M | 24.30M | 51.80M | 8.40M | 10.10M |
| 长期负债 | 2.08B | 2.38B | 1.98B | 1.85B | 1.66B | 1.81B |
| 总负债 | 4,081,900,000.00 | 4,473,000,000.00 | 3,942,500,000.00 | 3,731,100,000.00 | 3,627,900,000.00 | 3,617,100,000.00 |
| 股东权益总额 | 1.85B | 1.87B | 2.49B | 2.51B | 2.50B | 2.44B |
| 留存收益 | 2.42B | 2.42B | 2.35B | 2.36B | 2.36B | 2.29B |
现金流量表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 经营活动现金流 | 239.70M | 213.40M | 332.20M | 282.40M | 274.40M | 350.10M | 251.30M | 134.10M |
| 折旧与摊销 | 64.90M | 75.60M | 80.50M | 89.20M | 88.70M | 114.90M | 183.80M | 220.30M |
| 自由现金流 | 190.50M | 140.40M | 235.00M | 190.40M | 145.20M | 243.20M | 136.00M | 13.90M |
| 已派股息 | -25.10M | -25.00M | -24.60M | -24.20M | -29.80M | -29.40M | -30.20M | -32.90M |
| 股票回购/发行 | 9.40M | -131.40M | -119.90M | -146.30M | -263.10M | -142.80M | 409.00M | -2.10M |
| 期末现金余额 | 326.30M | 681.90M | 685.50M | 1.07B | 648.70M | 491.60M | 186.70M | 303.10M |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 经营活动现金流 | 65.00M | -127.50M | -33.20M | 229.80M | 71.20M | -77.40M |
| 折旧与摊销 | 50.40M | 56.10M | 55.70M | 58.10M | 58.30M | 58.00M |
| 自由现金流 | 39.00M | -148.80M | -54.10M | 177.80M | 47.00M | -106.20M |
| 已派股息 | -7.70M | -7.60M | 0 | -17.60M | -18.60M | -18.50M |
| 股票回购/发行 | -10.00M | -- | -- | 3.80M | 0 | -- |
| 期末现金余额 | 187.70M | 96.20M | 297.30M | 303.10M | 137.60M | 189.10M |
回报与效率指标
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 净资产收益率i | 22.16 | 21.87 | 16.90 | 27.28 | 27.16 | 34.30 | 7.16 | -1.06 |
| 总资产收益率i | 8.82 | 8.05 | 5.42 | 8.27 | 8.17 | 10.87 | 2.25 | -0.37 |
| 投入资本回报率i | 15.70 | 13.72 | 9.06 | 13.21 | 12.59 | 16.89 | 4.23 | 0.32 |
| 5年平均净资产收益率i | 15.14 | 18.11 | 18.76 | 19.87 | 23.07 | 25.50 | 22.56 | 18.97 |
| 息税前利润率i | 13.57 | 14.30 | 12.09 | 16.87 | 16.99 | 18.91 | 7.57 | 2.39 |
| 自由现金流/营收i | 10.05 | 6.77 | 11.82 | 7.87 | 5.74 | 8.20 | 4.04 | 0.40 |
| 流动比率i | 2.18 | 2.78 | 2.43 | 2.63 | 2.31 | 1.80 | 1.60 | 1.73 |
| 速动比率i | 1.13 | 1.62 | 1.35 | 1.69 | 1.36 | 0.92 | 0.69 | 0.81 |
| 资产负债率i | 16.02 | 31.78 | 29.94 | 38.19 | 35.17 | 32.46 | 38.67 | 32.73 |
| 长期负债权益比i | 35.98 | 94.82 | 92.52 | 118.04 | 110.91 | 89.68 | 122.43 | 81.05 |
| 利息保障倍数i | 20.42 | 18.53 | 16.68 | 28.52 | 26.71 | 34.18 | 5.32 | 1.36 |
| 营收复合年增长率(3年)i | 5.29 | 8.75 | 4.02 | 8.45 | 6.88 | 14.26 | 11.66 | 10.74 |
| 净利润复合年增长率(3年)i | 20.93 | 8.69 | 26.15 | 15.53 | 14.57 | 39.37 | -25.82 | -- |
| 自由现金流复合年增长率(3年)i | -0.78 | 14.43 | 28.52 | -0.02 | 1.13 | 1.15 | -10.61 | -54.25 |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 净资产收益率i | 4.93 | 4.43 | -1.12 | -1.06 | -1.71 | -5.11 |
| 总资产收益率i | 1.53 | 1.30 | -0.38 | -0.37 | -0.60 | -1.73 |
| 投入资本回报率i | 3.41 | 2.78 | 0.40 | 0.32 | -0.30 | -2.10 |
| 5年平均净资产收益率i | -- | -- | -- | -- | -- | -- |
| 息税前利润率i | 6.28 | 5.61 | 2.17 | 2.39 | 2.26 | 1.12 |
| 自由现金流/营收i | 5.07 | 1.43 | -- | 0.40 | 0.63 | 1.84 |
| 流动比率i | 1.57 | 1.61 | 1.85 | 1.73 | 1.55 | 1.85 |
| 速动比率i | 0.66 | 0.62 | 0.84 | 0.81 | 0.65 | 0.83 |
| 资产负债率i | 35.63 | 38.41 | 31.21 | 32.73 | 27.26 | 30.15 |
| 长期负债权益比i | 114.25 | 131.91 | 81.59 | 81.05 | 67.90 | 76.20 |
| 利息保障倍数i | 3.86 | 3.45 | 1.15 | 1.36 | 1.32 | 0.64 |
| 营收复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
| 净利润复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
| 自由现金流复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
✦ 量化营收集中度 计算方式说明
多元化
- 在披露的5个业务分部中，Bruker Scientific Instruments (BSI) Chemicals, Applied Markets,Life Science,In Vitro Diagnostics,是最大的一项，占营收的37.01%。
- 没有任何一项业务占营收过半；排名第二的Bruker Scientific Instrument (BSI) Nano占比31.16%，营收驱动力分布在多个业务板块上。
营收构成 最近报告期
业务分部
Bruker Scientific Instruments (BSI) Chemicals, Applied Markets,Life Science,In Vitro Diagnostics,37.01%
Bruker Scientific Instrument (BSI) Nano31.16%
Bruker Scientific Instruments (BSI) BioSpin23.34%
Bruker Energy & Supercon Technologies (BEST)8.85%
报价时间 2026-10-16 20:02:23 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Bruker 公司 讨论区 0 条评论